Research programme: facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio Therapies

Drug Profile

Research programme: facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio Therapies

Alternative Names: Facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio Therapies; FSHD therapeutics - Evotec AG/Facio Therapies

Latest Information Update: 14 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evotec AG; Facio Therapies
  • Class Small molecules
  • Mechanism of Action DUX4 protein inhibitors; SMCHD1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Facioscapulohumeral muscular dystrophy

Most Recent Events

  • 29 Apr 2015 Evotec AG and Facio Therapies agree to co-develop Facioscapulohumeral muscular dystrophy therapeutics
  • 29 Apr 2015 Early research in Facioscapulohumeral muscular dystrophy in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top